LivaNova (NASDAQ:LIVN) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a buy rating in a report published on Thursday.

A number of other brokerages also recently issued reports on LIVN. Needham & Company LLC reissued a buy rating and issued a $72.00 price target on shares of LivaNova in a report on Wednesday, March 20th. Barclays raised their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research note on Monday, February 26th. Robert W. Baird raised their target price on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a research note on Thursday, February 22nd. Finally, Mizuho reaffirmed a buy rating and issued a $75.00 target price on shares of LivaNova in a research note on Wednesday, March 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $64.40.

LivaNova Price Performance

LIVN opened at $55.53 on Thursday. The firm has a market cap of $3.00 billion, a P/E ratio of 173.54 and a beta of 0.89. The firm has a 50-day moving average of $54.13 and a 200 day moving average of $50.66. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $59.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. The company had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.81 earnings per share. On average, research analysts expect that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. New York State Teachers Retirement System raised its stake in shares of LivaNova by 0.3% during the first quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock worth $3,598,000 after acquiring an additional 200 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of LivaNova by 1.8% in the third quarter. Arizona State Retirement System now owns 15,309 shares of the company’s stock worth $810,000 after purchasing an additional 264 shares during the last quarter. State of Michigan Retirement System grew its holdings in shares of LivaNova by 2.3% in the first quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock worth $739,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of LivaNova by 2.6% in the first quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock worth $867,000 after purchasing an additional 400 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of LivaNova by 33.3% in the fourth quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock worth $93,000 after purchasing an additional 451 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.